Alpha Tau Medical (DRTS) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Alpha Tau Medical (NASDAQ: DRTS):

• 6/4/2026 – Alpha Tau Medical had its price target raised by Barclays PLC from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 6/2/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
• 5/28/2026 – Alpha Tau Medical is now covered by Barclays PLC. They set an “overweight” rating and a $15.00 price target on the stock.
• 5/28/2026 – Alpha Tau Medical is now covered by Barclays PLC. They set an “overweight” rating and a $15.00 price target on the stock.
• 5/20/2026 – Alpha Tau Medical had its “buy” rating reaffirmed by HC Wainwright. They now have a $15.00 price target on the stock.
• 5/19/2026 – Alpha Tau Medical had its price target raised by Piper Sandler from $5.00 to $8.00. They now have a “neutral” rating on the stock.
• 5/12/2026 – Alpha Tau Medical had its price target raised by LADENBURG THALM/SH SH from $12.00 to $14.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Alpha Tau Medical had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Alpha Tau Medical had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Activity at Alpha Tau Medical

In other news, CFO Raphi Levy sold 32,500 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00. Following the completion of the transaction, the chief financial officer owned 147,680 shares of the company’s stock, valued at approximately $1,599,374.40. This represents a 18.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 39.50% of the company’s stock.

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.